Plasma mid‐regional pro‐adrenomedullin: A biomarker of the ischemic penumbra in hyperacute stroke. (2nd August 2022)

• Record Type: Journal Article
• Authors: Ishiyama, Hiroyuki; Tanaka, Tomotaka; Saito, Satoshi; Koyama, Teruhide; Kitamura, Akihiro; Inoue, Manabu; Fukushima, Naoya; Morita, Yoshiaki; Koga, Masatoshi; Toyoda, Kazunori; Kuriyama, Nagato; Urushitani, Makoto; Ihara, Masafumi
• Other Names: Zeng Xianwei guestEditor.; Slevin Mark guestEditor.; Tu Wen‐Jun guestEditor.
• Is Part Of: Brain pathology. Volume 33:Number 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-02
• Subjects: acute ischemic stroke -- adrenomedullin -- blood biomarker -- ischemic penumbra; Nervous system -- Diseases -- Periodicals; Brain -- Diseases -- Periodicals; Neurology -- Periodicals; Brain Diseases -- Periodicals; Cerveau -- Maladies -- Périodiques; Système nerveux -- Maladies -- Périodiques; Neurologie -- Périodiques; 616.805
• DOI: 10.1111/bpa.13110
• Languages: English
• ISSNs: 1015-6305

Abstract

Abstract: Reperfusion therapy has improved the outcomes of ischemic stroke but also emphasized the importance of ischemic penumbra. However, blood biomarkers are currently unavailable for this region. Adrenomedullin (ADM) is a neuroprotective peptide, secreted in a compensatory response to brain ischemia. We thus investigated whether an increase in mid‐regional pro‐ADM (MR‐proADM), a stable peptide fragment of the ADM precursor, could act as a biomarker by predicting the ischemic penumbra in hyperacute ischemic stroke (HAIS). We prospectively enrolled consecutive HAIS patients ( n = 119; median age, 77 years; male, 59.7%) admitted to our institutes from July 2017 to March 2019 and evaluated plasma MR‐proADM levels within 4.5 h of onset. MR‐proADM levels in HAIS were compared to healthy controls ( n = 1298; median age, 58 years; male, 33.2%) in the Japan Multi‐Institutional Collaborative Cohort Study from 2013 to 2017. Furthermore, we evaluated whether MR‐proADM levels were associated with the penumbra estimated by clinical‐diffusion mismatch (CDM) (National Institute of Health Stroke Scale [NIHSS] ≥8, diffusion ischemic core volume ≤25 ml), or magnetic resonance angiography‐diffusion‐weighted imaging mismatch (MDM) (NIHSS ≥5, a proximal vessel occlusion with core volume ≤25 ml, or a proximal vessel stenosis/distal vessel occlusion with core volume ≤15 ml). In a case–control study, multivariate logistic analysis showed a significant association between HAIS and MR‐proADM ≥0.54 nmol/L (adjusted odds ratio, 7.92 [95% CI, 4.17–15.02], p < 0.001). Though MR‐proADM levels in HAIS did not correlate with the ischemic core volume ( r s = 0.09, p = 0.348), they were higher in HAIS with CDM ( n = 34; 0.81 vs. 0.61 nmol/L, p < 0.001) or MDM ( n = 26; 0.83 vs. 0.62 nmol/L, p = 0.002). These differences remained significant after adjusting baseline factors (adjusted odds ratio, 4.06 [95% CI, 1.31–12.55], p = 0.015 and 4.65 [1.35–16.11], p = 0.015, respectively). Plasma MR‐proADM is elevated in HAIS, especially in those with a substantial penumbra, suggesting potential as a blood biomarker in this region.